标签归档：hcaix

hCAIX/XII-IN-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX/XII-IN-1 

hCAIX/XII-IN-1 是一种有效的 CAIX/XII 抑制剂，KI 值分别为 0.48 µM 和 0.83 µM。hCAIX/XII-IN-1 显示出体外抗增殖活性。hCAIX/XII-IN-1 诱导 MCF-7 细胞凋亡apoptosis。

hCAIX/XII-IN-1

hCAIX/XII-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX/XII-IN-1 is a potent CAIX/XII inhibitor with the KI values of 0.48 µM and 0.83 µM for CAIX and CAXII, respectively. hCAIX/XII-IN-1 shows antiproliferative activity in vitro. hCAIX/XII-IN-1 induces apoptosis in MCF-7 cells[1].

IC50 & Target

KI: 0.48 µM (CAIX); 0.83 µM (CAXII)[1]
体外研究
(In Vitro)

hCAIX/XII-IN-1 (compound 11a) (3.125, 6.25, 12.5, 25, 50 µM, 48 h) shows antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells[1].
hCAIX/XII-IN-1 (0.48 µM; 24 h) increases the cell populations of Sub-G1 phase[1].
hCAIX/XII-IN-1 (0.48 µM) induces apoptosis in MCF-7 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: MCF-7 cells
Concentration: 3.125, 6.25, 12.5, 25, 50 µM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time: 24 h
Result: Significantly increased the cell populations of Sub-G1 phase.

Apoptosis Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time:
Result: Induced apoptosis in MCF-7 cells.

分子量

397.42

Formula

C19H11NO5S2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eldehna WM, et al. Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem. 2022; 37(1):531-541.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX/XII-IN-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX/XII-IN-1 

hCAIX/XII-IN-1 是一种有效的 CAIX/XII 抑制剂，KI 值分别为 0.48 µM 和 0.83 µM。hCAIX/XII-IN-1 显示出体外抗增殖活性。hCAIX/XII-IN-1 诱导 MCF-7 细胞凋亡apoptosis。

hCAIX/XII-IN-1

hCAIX/XII-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX/XII-IN-1 is a potent CAIX/XII inhibitor with the KI values of 0.48 µM and 0.83 µM for CAIX and CAXII, respectively. hCAIX/XII-IN-1 shows antiproliferative activity in vitro. hCAIX/XII-IN-1 induces apoptosis in MCF-7 cells[1].

IC50 & Target

KI: 0.48 µM (CAIX); 0.83 µM (CAXII)[1]
体外研究
(In Vitro)

hCAIX/XII-IN-1 (compound 11a) (3.125, 6.25, 12.5, 25, 50 µM, 48 h) shows antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells[1].
hCAIX/XII-IN-1 (0.48 µM; 24 h) increases the cell populations of Sub-G1 phase[1].
hCAIX/XII-IN-1 (0.48 µM) induces apoptosis in MCF-7 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: MCF-7 cells
Concentration: 3.125, 6.25, 12.5, 25, 50 µM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time: 24 h
Result: Significantly increased the cell populations of Sub-G1 phase.

Apoptosis Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time:
Result: Induced apoptosis in MCF-7 cells.

分子量

397.42

Formula

C19H11NO5S2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eldehna WM, et al. Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem. 2022; 37(1):531-541.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX/XII-IN-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX/XII-IN-1 

hCAIX/XII-IN-1 是一种有效的 CAIX/XII 抑制剂，KI 值分别为 0.48 µM 和 0.83 µM。hCAIX/XII-IN-1 显示出体外抗增殖活性。hCAIX/XII-IN-1 诱导 MCF-7 细胞凋亡apoptosis。

hCAIX/XII-IN-1

hCAIX/XII-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX/XII-IN-1 is a potent CAIX/XII inhibitor with the KI values of 0.48 µM and 0.83 µM for CAIX and CAXII, respectively. hCAIX/XII-IN-1 shows antiproliferative activity in vitro. hCAIX/XII-IN-1 induces apoptosis in MCF-7 cells[1].

IC50 & Target

KI: 0.48 µM (CAIX); 0.83 µM (CAXII)[1]
体外研究
(In Vitro)

hCAIX/XII-IN-1 (compound 11a) (3.125, 6.25, 12.5, 25, 50 µM, 48 h) shows antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells[1].
hCAIX/XII-IN-1 (0.48 µM; 24 h) increases the cell populations of Sub-G1 phase[1].
hCAIX/XII-IN-1 (0.48 µM) induces apoptosis in MCF-7 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: MCF-7 cells
Concentration: 3.125, 6.25, 12.5, 25, 50 µM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time: 24 h
Result: Significantly increased the cell populations of Sub-G1 phase.

Apoptosis Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time:
Result: Induced apoptosis in MCF-7 cells.

分子量

397.42

Formula

C19H11NO5S2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eldehna WM, et al. Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem. 2022; 37(1):531-541.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX-IN-3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX-IN-3 

hCAII-IN-3 (compound 7e) 是一种有效的、选择性的碳酸酐酶 (CA II/IX) 抑制剂，Kis 分别为 124.2 和 30.5 nM。hCAII-IN-3 具有研究癌症疾病的潜力。

hCAIX-IN-3

hCAIX-IN-3 Chemical Structure

CAS No. : 2375461-31-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases[1].

分子量

533.40

Formula

C21H21BrN6O4S
CAS 号

2375461-31-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Nocentini A, et al. Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors. Eur J Med Chem. 2020;186:111896.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX-IN-5

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX-IN-5 

hCAIX-IN-5 (compound 6b) 是一种有效的选择性 hCAIX 抑制剂，对 hCAI, hCAII，hCAIV，hCAIX 的 KIs 分别为 >10000, >10000, 130.7, 829.1 nM。

hCAIX-IN-5

hCAIX-IN-5 Chemical Structure

CAS No. : 2451479-57-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX-IN-5 (compound 6b) is a potent and selective hCAIX inhibitor with KIs of >10000, >10000, 130.7, 829.1 nM for hCAI, hCAII, hCAIV, hCAIX, respectively[1].

IC50 & Target

KI: >10000 nM (hCAI); >10000 nM (hCAII); 130.7 nM (hCAIV); 829.1 nM (hCAIX)[1]
分子量

309.29

Formula

C18H12FNO3
CAS 号

2451479-57-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Swain B, et al. New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation. Bioorg Med Chem. 2020 Aug 1;28(15):115586.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX-IN-7 

hCAIX-IN-7 (compound 6c) 是一种有效的选择性 hCAIX 抑制剂，对 hCAI, hCAII，hCAIV，hCAIX 的 KIs 分别为 >10000, >10000, 43.0, 410.6 nM。

hCAIX-IN-7

hCAIX-IN-7 Chemical Structure

CAS No. : 2451479-58-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX-IN-7 (compound 6c) is a potent and selective hCAIX inhibitor with KIs of >10000, >10000, 43.0, 410.6 nM for hCAI, hCAII, hCAIV, hCAIX, respectively[1].

IC50 & Target

KI: >10000 nM (hCAI); >10000 nM (hCAII); 43.0 nM (hCAIV); 410.6 nM (hCAIX)[1]
分子量

309.29

Formula

C18H12FNO3
CAS 号

2451479-58-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Swain B, et al. New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation. Bioorg Med Chem. 2020 Aug 1;28(15):115586.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX-IN-8

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX-IN-8 

hCAIX-IN-8 (compound 7i) 是一种有效的选择性 hCAIX 抑制剂，CAII、CAIX、CAVA 的IC50s 分别为 1.99, 0.024, 1.10 µM。hCAIX-IN-8 具有低毒性的抗增殖活性。hCAIX-IN-8 减少上皮细胞向间充质细胞的转化并诱导细胞凋亡 (apoptosis)。hCAIX-IN-8 抑制细胞迁移和定植。

hCAIX-IN-8

hCAIX-IN-8 Chemical Structure

CAS No. : 2414633-40-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX-IN-8 (compound 7i) is a potent and selective hCAIX inhibitor with IC50s of 1.99, 0.024, 1.10 µM for CAII, CAIX, CAVA respectively. hCAIX-IN-8 shows anti-proliferation activity with low toxicity. hCAIX-IN-8 decreases the epithelial to mesenchymal transitions and induces apoptosis. hCAIX-IN-8 inhibits cell migration and colonization potential[1].

IC50 & Target

IC50: 1.99 µM (CAII); 0.024 (CAIX), 1.10 µM (CAVA)[1]
体外研究
(In Vitro)

hCAIX-IN-8 (compound 7i) shows anti-proliferation activity with IC50是of 8.44, 11.22 µM for HT29, HepG2 cells, respectively[1].
hCAIX-IN-8 induces apoptosis in 24.44% and 19.22% of HT29 and HepG2 cells, respectivelysup>[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

396.35

Formula

C19H16N4O6
CAS 号

2414633-40-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Aneja B,et al. Design, synthesis & biological evaluation of ferulic acid-based small molecule inhibitors against tumor-associated carbonic anhydrase IX. Bioorg Med Chem. 2020 May 1;28(9):115424.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

hCAIX-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX-IN-6 

化合物6b和14g对肿瘤相关亚型hCA IX表现出显着的抑制作用，具有低纳摩尔效力，而6k对hCA XII有效。化合物6b，14g和6k可以被认为是基于新作用机制的未来癌症治疗药物发展的先导分子。

hCAIX-IN-6

hCAIX-IN-6 Chemical Structure

CAS No. : 2451479-86-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Compounds 6B and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6K was effective on HCA XII. Compounds 6B, 14g and 6K can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.

分子量

352.36

Formula

C18H12N2O4S
CAS 号

2451479-86-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Swain B,et al. New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation. Bioorg Med Chem. 2020 Aug 1;28(15):115586.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务